Umbro I, Tinti F, Mecule A, Bachetoni A, Poli L, Pignatelli A, Alessandri C, Fiacco F, D'Alessandro M, Di Natale V, Berloco P B, Valesini G, Mitterhofer A P
Department of Clinical Medicine, Nephrology and Dialysis Unit, 1st Faculty of Medicine and Surgery, Sapienza University of Rome, Rome, Italy.
Transplant Proc. 2012 Sep;44(7):1907-9. doi: 10.1016/j.transproceed.2012.06.054.
Conversion to tacrolimus (Tac) to once daily (Tac-O) formulation is commonly followed by a 20% reduction in Tac trough levels in the first month. It is not associated with modifications of renal function but there is the issue of its effects on inflammatory cytokines and on subclinical rejection. The aim of our study was to evaluate long-term interleukins (IL)-2 profiles in stable renal transplant patients after Tac-O conversion. We enrolled 10 stable kidney transplant patients converted to Tac-O. Tac trough levels, serum creatinine concentrations, glomerular filtration rate using the Modification of Diet in Renal Disease formula, C-reactive protein, IL-2 levels, and clinical assessments were performed monthly for 6 months before and 12 months after conversion. Despite the significant reduction in Tac trough levels, we did not observe alterations suggestive of clinical or subclinical acute rejection.
转换为他克莫司（Tac）每日一次（Tac-O）制剂后，通常在第一个月Tac谷浓度会降低20%。这与肾功能改变无关，但存在其对炎性细胞因子和亚临床排斥反应影响的问题。我们研究的目的是评估稳定的肾移植患者转换为Tac-O后白细胞介素（IL）-2的长期变化情况。我们纳入了10例转换为Tac-O的稳定肾移植患者。在转换前6个月和转换后12个月每月进行一次Tac谷浓度、血清肌酐浓度、使用肾脏病饮食改良公式计算的肾小球滤过率、C反应蛋白、IL-2水平及临床评估。尽管Tac谷浓度显著降低，但我们未观察到提示临床或亚临床急性排斥反应的改变。
